vimarsana.com

Page 60 - பல்கலைக்கழகம் கல்லூரி லண்டன் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Young Wexford respiratory consultant dies suddenly

Young Wexford respiratory consultant dies suddenly The son of a former Trinidad and Tobago Chief Justice was only 39 years old Tributes have been paid to a young respiratory consultant who died suddenly. Dr Keshav Sharma was 39 years of age when he passed away last week (January 11), three days after his birthday. He was a consultant respiratory and general medical physician at Wexford General Hospital (WGH). A spokesperson for the Ireland East Hospital Group has confirmed to Irish Medical Times that the death was not related to Covid-19. “All the staff and management in Wexford General Hospital were profoundly sad to learn of the sudden passing of Dr Keshav Sharma this week,” the spokesperson added.

Digital healthcare training is key to successful EPR go-live

Digital healthcare training is key to successful EPR go-live In a recent webinar, NHS chief information officers outlined the challenges they encountered with training staff for big system go-lives and learned how uPerform by ANCILE Solutions could help to address them. By:  10:14 AM Research suggests that 70% of the success of an electronic patient record (EPR) project can rest on effective user adoption. In a recent webinar hosted by ANCILE Solutions, healthcare experts discussed the challenges faced in running traditional training programmes and Bobby Zarr, senior director of healthcare strategy at ANCILE Solutions, described how uPerform helped him prepare for an Epic go-live at Infirmary Health in the US.

Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure

Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure Orally-administered, non-absorbable engineered carbon, Carbalive , was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis Safety of novel dual filtration system, Dialive , confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group London, UK, 7 January 2021 - Yaqrit, a clinical stage life sciences company focused on developing potentially innovative treatments for patients with advanced liver disease in areas of high unmet medical need, today announces preliminary results from its randomised controlled clinical trials for two potential therapies from its pipeline of product candidates designed to address each stage of liver disease, from diagnosis of decompensated c

Investegate |Yaqrit Discovery Ltd Announcements | Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure

Yaqrit Discovery Ltd Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure  Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure  Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure  Orally-administered, non-absorbable engineered carbon, Carbalive ™, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis Safety of novel dual filtration system, Dialive ™, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group  

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.